ASAndrey Stanzhevskiy

Andrey Stanzhevskiy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andrey Stanzhevskiy has a total of 136 co-authors. Here are the top co-authors by number of shared publications:

  • Dmitrii N. Maistrenko

    Federal State Budgetary Institution «Russian Scientific Center of Radiology and Surgical Technolo-gies named after Academician A. M. Granov» Ministry of Health of the Russian Federation, Sankt-Peterburg

    26 shared publications
  • Larisa A. Chipiga

    Saint Petersburg Research Institute of Radiation Hygiene after Professor P.V. Ramzaev, Federal Service for Surveillance of Consumer Rights Protection and Human Wellbeing

    14 shared publications
  • Alexandr Valerievich Vodovatov

    Saint Petersburg Research Institute of Radiation Hygiene after Professor P.V. Ramzaev, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing; Saint Petersburg State Pediatric Medical University

    12 shared publications
  • Aleksey D. Maystrenko

    Federal State Budgetary Institution «Russian Scientific Center of Radiology and Surgical Technolo-gies named after Academician A. M. Granov» Ministry of Health of the Russian Federation, Sankt-Peterburg

    9 shared publications
  • Alyona A. Popova

    Federal State Budgetary Institution «Russian Scientific Center of Radiology and Surgical Technolo-gies named after Academician A. M. Granov» Ministry of Health of the Russian Federation, Sankt-Peterburg

    8 shared publications
  • Anastasiya V. Petryakova

    Saint-Petersburg Research Institute of Radiation Hygiene after Professor P.V. Ramzaev, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing; The City Hospital No 40 of the Kurortny District

    8 shared publications

Latest Publications

  • Open Access

    Evaluation of the radioprotective efficacy of water soluble sodium salt of n-acetylcysteine in experimental studies

    by A. A. Popova, L. A. Chipiga, D. N. Maystrenko, V. I. Evtushenko, A. A. Stanzhevskiy, D. N. Nikolaev, T. E. Ponezha, Yu. N. Vinogradova, E. B. Ioffe, A. D. Maistrenko

    Although several radioprotectors have been developed, their clinical use remains limited due to toxicity, a narrow therapeutic window, and reduced efficacy when administered post irradiation. Consequently, there is a pressing need to develop novel radioprotective agents with improved safety and effectiveness.    The aim of this study was to evaluate the radioprotective efficacy of water-soluble sodium salt n-acetylcysteine (NAC).    Materials and Methods: The study was conducted on 252 male Wistar rats to determine the radioprotective dose of sodium n-acetylcysteine, assess the effectiveness of its prophylactic administration prior to gamma irradiation, and analyze the dynamics of hematological parameters in peripheral blood. The drug was administered intraperitoneally 1 or 3 hours before irradiation, or 1 hour after exposure. Irradiation was performed using an IGUR-1 device at a dose of 7.0 Gy (LD 95–100/30 ). The working solution of sodium n-acetylcysteine (300 mg/mL, pH 7.5) was prepared ex tempore by dissolving 3 g of the dry substance in 3 mL of distilled water, followed by the addition of 3.5 mL of 5N NaOH and titration to the required pH.   Results and Discussion: Intraperitoneal administration of sodium n-acetylcysteine at a dose of 2500 mg/kg contributed to partial preservation of hematopoiesis in animals exposed to 7.0 Gy (LD 95–100/30 ), promoted maintenance of the hematopoietic cell pool, and accelerated the recovery process. Evaluation of the specific radioprotective activity showed that administration at a dose of 2000 mg/kg provided 42 % survival in animals exposed to a lethal radiation dose.    Conclusion: The findings in rats demonstrate the rationale for further investigation of the pharmacodynamic properties of sodium n-acetylcysteine, highlighting its significant potential as a radioprotective agent.

  • Modern hemostatic agents for controlling various types of surgical bleeding

    by D.N. Maystrenko, A.A. Popova, D.N. Nikolaev, V.V. Georgobiani, V.I. Evtushenko, M.I. Generalov, A.D. Maystrenko, A.S. Ivanov, A.A. Stanzhevskiy, V.N. Polysalov, et al.

    Hemorrhage control is a critically important task in surgery, traumatology, and emergency medicine. Blood loss resulting from injuries, surgeries, childbirth, or pathological conditions can lead to shock, multiple organ failure, and death. Modern hemostatic agents play a key role in reducing blood loss, improving treatment outcomes, and shortening surgical procedure times. Purpose of the study: to review and systematize literature data on hemostatic agents used in surgical practice and emergency medicine, and to classify them according to their main active ingredients and forms of release. Materials and methods. The review analyzes data from the past 10-15 years (2011–2026) sourced from scientific databases (PubMed, CyberLeninka, Google Scholar, ScienceDirect, eLibrary), official manufacturers’ instructions, and patents. The study examines agents based on collagen, gelatine, cellulose, chitosan, kaolin, zeolite, and other substances. Results. Despite significant progress in the field of hemostatic agents, there remains a need for further research to develop safer, faster-acting, and more cost‑effective products.

  • Evaluation of the physico-mechanical and hemostatic properties of a local adhesive hemostatic agent based on chitosan and polymer compositions

    by Dmitry N. Nikolaev, Николаев Дмитрий Николаевич, Victoria V. Georgobiani, Георгобиани Виктория Владимировна, Dmitrii N. Maistrenko, Майстренко Дмитрий Николаевич, Vladimir I. Evtushenko, Евтушенко Владимир Иванович, Alexander S. Ivanov, Иванов Александр Сергеевич, et al.

    BACKGROUND: Developing effective local hemostatic agents for widespread use both pre-hospital and during surgeries is a pressing issue in modern medical practice. Currently available hemostatic agents based on collagen, cellulose, clotting factors, chitosan, and alginate have significant limitations, including insufficient efficacy. AIM: To conduct a comparative analysis of the physical and mechanical properties of the new local hemostatic agent in the form of a bilayer film and similar products in vitro, and to evaluate its hemostatic efficacy in an acute animal experiment. METHODS: The physical and mechanical (adhesive and deformation) properties of the new hemostatic agent and similar products were evaluated in vitro on a stand with a tensile testing machine. Hemostatic efficacy was evaluated in vivo in models of large vessel injury in a deep wound and parenchymal organ injury using 30 Wistar rats (body weight 250–300 g, of both sexes), and 12 male Vietnamese pot-bellied pigs (body weight 40–60 kg). RESULTS: In vitro tests confirmed the high adhesion of the new hemostatic agent to biological surfaces compared with known analogs, its resistance to mechanical stress, and preservation of functional integrity under deformation. The mean force required to detach the sample was 7.77 N, and the residual deformation coefficient was 1.8%. In an acute animal experiment, the agent demonstrated high hemostatic efficacy in large vessel injury and parenchymal organ injury: bleeding was completely controlled within a few minutes, with formation of a stable fibrin clot. Observation for 3–4 hours revealed no signs of recurrent bleeding, confirming reliable hemostasis. The agent firmly adhered to the wound channel walls, providing mechanical stabilization of injured tissues. CONCLUSION: A composite hemostatic film has been developed for emergency control of massive bleeding in surgery of parenchymal organs and major vessels. The composition demonstrates versatility (applicable to the liver, kidneys, spleen, and major vessels) and can be used for temporary or definitive hemostasis. The inclusion of L-arginine, silicon dioxide, polyethylene glycol, and ferric chloride enhances hemostatic activity, adhesion, and elasticity.

  • Open Access

    Potential of Dual-Phase 68Ga-FAPI PET/CT in the Differential Diagnosis of Focal Liver Lesions

    by A. A. Ivanova, D. V. Ryzhkova, K. E. Sanarova, I. O. Rutkin, A. A. Stanzhevskii, A. A. Maystrenko, D. N. Maystrenko

    Introduction. Recent studies have confirmed the effectiveness of positron emission tomography combined with computed tomography (PET/CT) using radiolabeled ligands of fibroblast activation protein inhibitors (FAPI) for the visualization of malignant lesions (ML) and benign lesions (BL). The objective was to evaluate the diagnostic utility of dual-phase PET/CT with 68 Ga-FAPI-04 in patients with focal liver lesions of varying etiology. Methods and materials. The study enrolled 62 patients with focal liver lesions of diverse etiologies for the purpose of differential diagnosis (20/62 patients) and pretreatment staging (42/62 patients). 68 Ga-FAPI-04 PET/CT imaging was performed in two phases: Phase I (PET/CT 20 ) – imaging began 20 minutes after administration of 68 Ga-FAPI-04 (limited to the abdominal region); Phase II (PET/CT 60 ) – 60 minutes after injection, performed as a «Whole-body» scan. Image analysis included visual assessment and calculation of the maximum standardized uptake value (SUVmax) over the lesion areas. Results. Comprehensive clinical and imaging evaluation identified a total of 128 focal liver lesions. At the early-phase PET/CT scan (PET/CT 20 ), increased 68 Ga-FAPI-04 uptake was observed in 109 of 128 lesions (85.2 %): 18 of 25 BL and 91 of 103 ML. A comparable uptake pattern was seen on the delayed-phase scan (PET/CT 60 ): 18 of 25 BL and 93 of 103 ML. Visual and quantitative analyses of dual-phase 68 Ga-FAPI-04 PET/CT demonstrated no significant differences in sensitivity, specificity, and diagnostic accuracy between phase I and phase II for the differential diagnosis of focal liver lesions. Visual assessment yielded values of 88.3 %, 28 %, 76.6 % for phase I versus 90.3 %, 28 %, 78.1 % for phase II. Quantitative analysis of 68 Ga-FAPI-04 uptake intensity in hepatic lesions showed corresponding values of 73.8 %, 64 %, 74.2 % for phase I and 68 %, 72 %, 71.6 % for phase II. Conclusion: Elevated 68 Ga-FAPI-04 uptake was observed in the majority of hepatic lesions during both early and delayed imaging phases, irrespective of lesion etiology. Given the absence of significant diagnostic gain between time points, dual-phase PET/CT acquisition appears unnecessary for differentiating the etiology of liver lesions. Quantitative assessment using SUVmax values contributes to improved specificity of 68 Ga-FAPI-04 PET/CT in identifying malignant hepatic involvement.

  • New device to stop massive bleeding from major arteries

    by V. I. Evtushenko, D. N. Maistrenko, D. N. Nikolayev, A. A. Popova, V. V. Georgobiani, M. I. Generalov, A. D. Maystrenko, A. S. Ivanov, A. A. Stanzhevskiy, V. N. Polysalov, et al.

    The problem of local hemostasis remains highly relevant, with a steady increase in scientific and practical interest in its solution observed in recent years. This is driven by two key factors: limited access to modern foreign hemostatic products and an insufficient supply of domestic analogues that meet the basic requirements of clinical practice — efficacy, adhesiveness, ease of use, biocompatibility, and safety. A new hemostatic agent, a hemostatic sponge made from domestic materials and meeting the specified conditions, was developed at the laboratory of medical instrument engineering of the FSBI «RSCRT named after A. M. Granov» of the Ministry of Health of Russia. The aim of this study was to conduct a comprehensive investigation of the properties of the developed hemostatic sponge in an acute in vivo experiment. Materials and methods. The study was performed on 23 male Wistar rats weighing 250–300 g and on 10 male Vietnamese Pot-bellied pigs weighing 70–80 kg. Hemostatic efficacy and adhesion were studied using a model of large vessel injury in a deep wound, as well as in parenchymal organ damage (liver, spleen). Toxic effects were assessed by implanting the sponge into the scruff of the neck of 10 Wistar rats, not included in the main group, followed by observation. The study results showed that the product meets modern requirements for topical hemostatic agents: it combines rapid action, safety, versatility, and economic feasibility (due to the use of domestic materials). Its introduction into clinical practice could improve the effectiveness of bleeding control in various surgical fields.

  • Imaging of active bioprosthetic valve degeneration using 68GA-FAPI-04 PET/CT: a pilot study of pathophysiological mechanisms and diagnostic value

    by A. D. Majstrenko, A. A. Ivanova, A. A. Stanzhevskij, V. E. Uspenskij, D. V. Ryzhkova, A. A. Popova, E. B. Ioffe, V. V. Zjuleva, A. Ju. Kneev, M. Gordeev

    Structural valve deterioration (SVD) remains the major limitation of bioprosthetic heart valves (BHV). Current imaging modalities (Echocardiography, CT) detect SVD at late stages of irreversible damage. This study aimed to evaluate the potential of 68Ga-FAPI-04 PET/CT, a marker of fibroblast activation, for the early visualization of active BHV remodeling and to assess its correlation with hemodynamic dysfunction. We performed a cross-sectional analysis of 30 patients with implanted aortic BHVs. All patients underwent transthoracic echocardiography and 68Ga-FAPI-04 PET/CT. Tracer uptake was quantified using the Differential Uptake Ratio (DUR). Statistical analysis included Spearman’s rank correlation, partial correlation to adjust for confounders, bootstrap analysis (5,000 resamples) for verification, and ROC analysis to determine diagnostic accuracy. DUR demonstrated a statistically significant positive correlation with peak transprosthetic pressure gradient (rs = 0.404, p = 0.027). Notably, an inverse correlation was observed between DUR and Left Ventricular Ejection Fraction (rs =–0.411, p = 0.024). Partial correlation analysis confirmed that the association between DUR and prosthetic gradients remained significant (rpartial = 0.385, p = 0.036) even after adjusting for LVEF, indicating that tracer uptake reflects intrinsic valve pathology rather than systemic heart failure. The intensity of FAP-targeted signal did not correlate with patient age or time since implantation (p >0.05). Specificity analysis showed no association between DUR and comorbidities (diabetes, renal failure) or gender. ROC analysis yielded an AUC of 0.682 (95 % CI: 0.478–0.887) for detecting severe dysfunction, with an optimal cut-off value of DUR > 2.35. The method visualizes active fibroblast-mediated remodeling in bioprosthetic valves, which correlates with hemodynamic deterioration but occurs independently of chronologic valve age and provides a specific molecular signal of SVD that is distinct from systemic factors or cardiac performance artifacts.

  • The first results of the study of a new domestic adhesive haemost atic agent «Haemostatic Film»

    by D. N. Nikolayev, V. V. Georgobiani, D. N. Maistrenko, V. I. Evtushenko, A. A. Stanzhevskiy, A. A. Popova, A. S. Ivanov, M. I. Generalov, A. D. Maystrenko

    The article presents the first results of a study on a novel domestic topical adhesive haemostatic agent — «Haemostatic Film». The formulation is based on chitosan, arginine, polyethylene glycol, silicon dioxide, and iron chloride, structured as a double‑layered plate that ensures high adhesion to moist biological surfaces. The aim. To develop an effective, inexpensive, and atraumatic agent for controlling haemorrhages of various aetiologies (capillary, venous, arterial, and parenchymal). Materials and methods. The haemostatic efficacy and adhesive properties of the developed chitosan‑based composite agent were evaluated in vivo using models of major vessel injuries in deep wounds, as well as in cases of parenchymal organ damage. The study was conducted on 30 Wistar rats (both sexes, body weight 250‑300 g) and 12 male Vietnamese pot‑bellied pigs (body weight 40‑60 kg). Results. The application of the developed topical haemostatic agent demonstrated high haemostatic efficacy in both major vessel injuries and parenchymal organ wounds. Bleeding was completely stopped within several minutes, accompanied by the formation of a stable fibrin clot. Subsequent observation of the animals over 3‑4 hours revealed no signs of bleeding recurrence, confirming the reliability of haemostasis. The agent exhibited strong adhesion to the wound canal walls, providing mechanical stabilisation of damaged tissues. Conclusion. The developed adhesive haemostatic film, based on chitosan, arginine, polyethylene glycol, silicon dioxide, and iron chloride, demonstrated versatility in the studies (applicable to the liver, kidneys, spleen, and major vessels), the possibility of atraumatic removal, and adaptability — it can function as either temporary or definitive haemostasis.

  • Open Access

    Fetus doses from radionuclide diagnostic of pregnant patients

    by L. A. Chipiga, E. K. Milovanova, I. A. Zvonova, A. V. Vodovatov, D. A. Vazhenina, A. A. Stanzhevsky

    The aim of the work was to estimate the radiation doses to the fetus during radionuclide diagnostic procedures in pregnant patients. Materials and Methods: The absorbed doses to the fetus due to the radiopharmaceutical administered to the mother during radionuclide diagnostic procedures were estimated for the most common procedures performed in the Russian Federation using the conversion factors from the administered activity of radionuclides in the radiopharmaceutical to the absorbed dose. Typical values of the administered activities of radionuclides for each radiopharmaceutical and the conversion factors taking into account the stage of pregnancy of the patient at which the study was conducted were used. For comparison, the absorbed doses to the mother's uterus, as the closest organ, were determined. For hybrid studies, the absorbed doses to the fetus from maternal CT scans at different stages of pregnancy were calculated in the FetalDose program for typical scanning protocols for adult patients. Results and Discussion: The absorbed doses to the fetus from the administered radiopharmaceutical for most studies do not exceed 20 mGy. In hybrid studies where the CT scan area includes the abdominal region, the CT dose is the largest contributor to the total dose, justifying a scan area limitation or low-dose protocols for whole-body scanning. An exception is the 67Ga-citrate study, where the absorbed dose to the fetus may exceed 50 mGy, with the largest contribution to the dose coming from the maternally administered radiopharmaceutical. Conclusion: The results obtained indicate that for most nuclear medicine procedures, the risks of deterministic effects in the fetus or stochastic effects in the child from the maternal diagnostic examination are minimal. It is advisable to assess doses and risks for each individual patient, taking into account the clinical situation and radiographic history.


  • Open Access

    The geography and structure of nuclear medicine centres in the Russian Federation in 2025

    by L. A. Chipiga, K. N. Kozlova, I. A. Zvonova, A. V. Vodovatov, A. M. Biblin, A. A. Stanzhevsky

    The development of nuclear medicine has led to an increase in the use of open radionuclide sources and the associated processes of transporting ionising radiation sources and generating radioactive waste. This situation leads to focus on monitoring and accounting of ionising radiation sources in hospitals. The aim of the study was assessment of geographical distribution and structure of nuclear medicine centres in theRussian Federation. Material and Methods: The register of sanitary and epidemiological conclusions on the compliance (non-compliance) of activities (works, services) with the requirements of state sanitary and epidemiological rules and regulations were analyzed at the beginning of 2025. Results: 188 hospitals operated with radionuclide, are located in the Russian Federation in 2025, including 152 single photon diagnostic nuclear medicine departments (38 in Moscow and 20 in St. Petersburg); 81 positron emission tomography departments (26 in Moscow and 8 in St. Petersburg); 52 radiopharmaceutical therapy departments (12 departments in Moscow and 5 in St. Petersburg). According to the results of the study, all radiopharmaceutical therapy departments are based in diagnostic nuclear medicine centers. Conclusion: The current practice of organizing radiopharmaceutical therapy units based on diagnostic nuclear medicine units does not allow to consider the radiation safety issues separately for diagnostics and therapy. It is reasonable to have uniform requirements for nuclear medicine units


  • Open Access

    Modeling of acute radiation syndrome in experiment

    by A. A. Popova, L. A. Chipiga, D. N. Maystrenko, A. A. Stanzhevskiy, O. E. Molchanov, D. N. Nikolaev, T. E. Ponezha, Yu. N. Vinogradova, E. B. Ioffe

    The aim of the current study was to create a new and easily reproducible method of modeling acute radiation syndrome, representing the features of the clinical flow of this disease. Materials and Methods: A series of experiments on Wistar rats, both genders (nursery “Rappolovo” (Leningrad region), weight 180–220 g), were performed. Rats were divided into groups and one time exposed at the investigated dose (range of 6–10 Gy) on Elekta Precise accelerator using Solid Water HE (Sun Nuclear) 30×30 cm2 phantom plates. The duration of animal observation was 30 days. Survival, mean lifespan, body weight dynamics, feed and water consumption, state of visible mucous membranes, hair coat and mobility were evaluated. Results and Discussion: The results showed that the proposed model of single exposure of laboratory rats demonstrates a good level of results reproducibility and complies with the basic requirements for experimental models. The lethality of rats within 30 days was 75% with a dose of 8 Gy, the 100% lethality of rats was with a dose of 10 Gy. The results are successfully reproduced in repeated experiments. Conclusion: The obtained data indicated that the proposed model is reliable and can be used for preclinical studies of radioprotectors without existing models’ problem of variability of results.